ArticleWorld journal of hepatology2015
Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications.
Article in World journal of hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed.
- Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment.Clinical pharmacokinetics · 2021Trial
- Quantitative Measure of Intestinal Permeability Using Blue Food Coloring.The Journal of surgical research · 2019Trial
- Review
- The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Microbiome Interactions and Therapeutic Targets.Probiotics and antimicrobial proteins · 2026Review
- Gut microbiota and postoperative delirium: mechanistic integration of the "gut-liver-anesthesia axis" in the context of liver disease and perioperative intervention strategies.Frontiers in medicine · 2026Review
- The Role of the Gut Microbiome Dysbiosis in Metabolic Dysfunction: A Mini Review.Healthcare (Basel, Switzerland) · 2025Review
- New developments on the effects of alcohol use on immunity, inflammation and organ function: A summary of the 2024 Alcohol and Immunology Research Interest Group (AIRIG) meeting.Alcohol (Fayetteville, N.Y.) · 2025Article
- Infection risk and management in patients with cirrhosis: A critical overview.World journal of hepatology · 2025Article
- Article
- Gut microbiota, liver disease, and perioperative anesthesia: interactions, risks, and therapeutic opportunities.Frontiers in cellular and infection microbiology · 2025Review
- Alcohol-Associated Hepatitis: Translating Pathophysiology into Targeted Clinical Trials.Current hepatology reports · 2025Review
- Microbiota composition and intestinal barrier function modulated by tamsulosin andFrontiers in cellular and infection microbiology · 2025Article
- Goblet cells: guardians of gut immunity and their role in gastrointestinal diseases.eGastroenterology · 2024Article
- Infections in decompensated cirrhosis: Pathophysiology, management, and research agenda.Hepatology communications · 2024Review
- The role of gut barrier dysfunction in postoperative complications in liver transplantation: pathophysiological and therapeutic considerations.Infection · 2024Review
- Potential mechanisms of traditional Chinese medicine in the treatment of liver cirrhosis: a focus on gut microbiota.Frontiers in microbiology · 2024Review
- Changes of the bacterial composition in duodenal fluid from patients with liver cirrhosis and molecular bacterascites.Scientific reports · 2023Article
- Circulating neutrophil anti-pathogen dysfunction in cirrhosis.JHEP reports : innovation in hepatology · 2023Review
- Imeglimin: A Clinical Pharmacology Review.Clinical pharmacokinetics · 2023Review
- Alcohol-associated bowel disease: new insights into pathogenesis.eGastroenterology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The intestinal lumen is a host place for a wide range of microbiota and sets a unique interplay between local immune system, inflammatory cells and intestinal epithelium, forming a physical barrier against microbial invaders and toxins. Bacterial translocation is the migration of viable or nonviable microorganisms or their pathogen-associated molecular patterns, such as lipopolysaccharide, from the gut lumen to the mesenteric lymph nodes, systemic circulation and other normally sterile extraintestinal sites. A series of studies have shown that translocation of bacteria and their products across the intestinal barrier is a commonplace in patients with liver disease. The deterioration of intestinal barrier integrity and the consulting increased intestinal permeability in cirrhotic patients play a pivotal pathophysiological role in the development of severe complications as high rate of infections, spontaneous bacterial peritonitis, hepatic encephalopathy, hepatorenal syndrome, variceal bleeding, progression of liver injury and hepatocellular carcinoma. Nevertheless, the exact cellular and molecular mechanisms implicated in the phenomenon of microbial translocation in liver cirrhosis have not been fully elucidated yet.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.